Analysts' ratings for Regenxbio (NASDAQ:RGNX) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
4
2
0
0
Last 30D
1
0
0
0
0
1M Ago
0
0
0
0
0
2M Ago
2
4
2
0
0
3M Ago
0
0
0
0
0
The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.22, a high estimate of $55.00, and a low estimate of $21.00. This current average has increased by 1.25% from the previous average price target of $37.75.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain insights into how financial experts perceive Regenxbio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Annabel Samimy
Stifel
Maintains
Buy
$40.00
-
Yi Chen
HC Wainwright & Co.
Announces
Buy
$36.00
-
Luca Issi
RBC Capital
Raises
Outperform
$35.00
$20.00
Daniil Gataulin
Chardan Capital
Maintains
Buy
$52.00
$52.00
Gena Wang
Barclays
Raises
Overweight
$55.00
$45.00
Brian Skorney
Baird
Raises
Outperform
$39.00
$34.00
Andreas Argyrides
Wedbush
Maintains
Neutral
$21.00
-
Dane Leone
Raymond James
Announces
Outperform
$45.00
-
Andreas Argyrides
Wedbush
Maintains
Neutral
$21.00
-
Key Insights:
Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects ...Full story available on Benzinga.com
Related tickers: RGNX.
Read Full Article